Tag archive for ‘Impavido’
By The Dispatch On Saturday, December 17th, 2016

Profounda receives FDA Orphan Drug Designation for miltefosine for treating Primary Amebic Meningoencephalitis (PAM)

Profounda, Inc. announced Friday that it has received, the US Food and Drug Administration’s (FDA) Orphan Drug Designation for the treatment of Primary Amebic Meningoencephalitis (PAM) with miltefosine.  More...

By The Dispatch On Wednesday, March 19th, 2014
1 Comment

Impavido to treat leishmaniasis receives FDA approval

PRESS RELEASE The U.S. Food and Drug Administration today approved Impavido (miltefosine) to treat a tropical disease called leishmaniasis. Phlebotomus papatasi sand flyImage/CDC Leishmaniasis is a disease caused More...

Recent Posts


Splash Page logo 300x146 Today in History